Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC) - Episode 4

Biomarker Testing Strategies for Lung LCNEC

December 2, 2024

Martin Dietrich, MD, PhD, Soo-Ryum Yang, MD

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.

EP. 1: Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

EP. 2: An Overview of the Molecular Characterization of Lung LCNEC

EP. 3: The Pathological Diagnosis of Lung LCNEC

Now Viewing

EP. 4: Biomarker Testing Strategies for Lung LCNEC

EP. 5: Biopsy Best Practices: Diagnosing Lung LCNEC

EP. 6: Lung LCNEC Diagnostic Challenges

EP. 7: A Multidisciplinary Approach to Managing Lung LCNEC

EP. 8: Lung LCNEC Disease Histology and Prognosis

EP. 9: The Role of DLL3 in LCNEC of the Lung

EP. 10: Insights on the LANCE Pilot Study on Lung LCNEC

Please describe your general biomarker testing strategy for lung LCNEC.
How often do you perform biomarker testing and what tests do you employ (eg, NGS, etc)?
What do you test for?
When do you test for DLL3?
How often do you see DLL3+ patients in your practice?